Radiopharm Completes Productive End-of-Phase 2 Meeting with U.S. Food and Drug Administration for Pivotal Development Program of RAD101

Go back to Radiopharm Completes Productive End-of-Phase 2 Meeting with U.S. Food and Drug Administration for Pivotal Development Program of RAD101
(NASDAQ: RADX) Delayed: 0.98 -0.01 (1.01%)
Previous Close $0.99    52 Week High $ 
Open $0.96    52 Week Low $ 
Day High $1.01    P/E N/A 
Day Low $0.90    EPS $ 
Volume 14,360